Pneumococcal conjugate vaccine

Sugary handshakes are how cells talk to each other − understanding these name tags can clarify how the immune system works

Retrieved on: 
Thursday, February 8, 2024

Unlike people, cells perform these handshakes using the diverse range of sugar molecules coating their surface like trees covering a landscape.

Key Points: 
  • Unlike people, cells perform these handshakes using the diverse range of sugar molecules coating their surface like trees covering a landscape.
  • Handshakes between these sugar molecules, or glycans, trigger cells to react in specific ways toward each other, such as escape, ignore or destroy.

What are glycans?

  • The vast number of possible glycan structures that can be built from connecting these sugar molecules together allows glycans to store rich information.
  • Glycans are chemically bonded to proteins and lipids on the surface of red blood cells.
  • Notably, the surface of type A red blood cells have glycans that differ from the glycans on the surface of type B and type O red blood cells.
  • For example, distinctive glycoproteins cover the surface of the viruses that cause COVID-19, HIV and H1N1 influenza and help them infect cells.
  • Glycolipids also coat many bacteria, allowing them to stick to their hosts and protect them from viruses and immune cells.

How do cells read glycans?

  • Found on surfaces of certain immune cells, these lectins deliver the glycans to proteins on other immune cells that can now selectively destroy any viruses or cells that carry that glycan.
  • For example, these lectins recognize glycans on the surfaces of cancer cells and direct other immune cells to eliminate these cancer cells.
  • Another type of lectin called siglecs are found on surfaces of immune cells and help them distinguish self from nonself, that is, between the cells that make up the body and the cells that are foreign to the body.
  • The bacterial glycans in the vaccine trigger an immune response when immune cells recognize the glycans as foreign threats.

Examining every sugar molecule

  • Comprehensively extracting all the information stored in glycans is very difficult because there isn’t currently technology able to analyze the complex and diverse structures of glycans.
  • Individual glycans are composed of sugar molecules in unique arrangements, but current analytical tools can only simultaneously analyze many glycans.


My lab is confronting this challenge by developing imaging technology that can analyze the structure of glycans by imaging each individual molecule. Essentially, we’re developing a technique to open the jar and study every single candy one at a time. In the long run, my team aspires to unveil how these glycans present themselves to the proteins that recognize them and, finally, reveal the very language that cells use to express themselves.
Kelvin Anggara works for the Max Planck Institute for Solid State Research and receives funding from the European Research Council under Project GlycoX (101075996).

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 8, 2023

-- $949.9 Million in Cash, Cash Equivalents and Investments as of March 31, 2023, Excluding Net Proceeds of $545.1 Million from Recent Public Offering --

Key Points: 
  • VAX-24, the Company’s lead, broad-spectrum 24-valent pneumococcal conjugate vaccine (PCV) candidate, is being studied for the prevention of IPD.
  • Submission of the adult IND application to the FDA and announcement of subsequent FDA clearance in the second half of 2023.
  • The March 31, 2023 amount excludes the $545.1 million in estimated net proceeds from the follow-on offering completed in April 2023.
  • Net Loss: For the three months ended March 31, 2023, net loss was $60.5 million, compared to $39.0 million for the same period in 2022.

U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

Retrieved on: 
Thursday, April 27, 2023

“Today's FDA approval of our vaccine, PREVNAR 20, now offers parents the ability to help protect their children against 20 pneumococcal serotypes in circulation, which represent the majority of pneumococcal disease in U.S. infants and children,"1,2 said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer.

Key Points: 
  • “Today's FDA approval of our vaccine, PREVNAR 20, now offers parents the ability to help protect their children against 20 pneumococcal serotypes in circulation, which represent the majority of pneumococcal disease in U.S. infants and children,"1,2 said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer.
  • “This important PREVNAR 20 approval builds on more than 20 years of real-world impact with PREVNAR and PREVNAR 13, safety data, and effectiveness; highlighting Pfizer's leadership in developing groundbreaking pneumococcal conjugate vaccines to help protect infants and their families from life threatening infections.
  • "We are thrilled with this approval as it signifies a new chapter in pediatric pneumococcal conjugate vaccination.
  • Further positive data from a Proof-of-Concept Phase 2 study (NCT03512288) that assessed the safety and immunogenicity of PREVNAR 20 also supported the FDA’s decision.

African vaccines: local manufacturers are struggling to access the market - what must change

Retrieved on: 
Tuesday, April 25, 2023

The hub was launched in mid-2021 in a bid to make the latest vaccine technology more readily available to developing countries.

Key Points: 
  • The hub was launched in mid-2021 in a bid to make the latest vaccine technology more readily available to developing countries.
  • The other development highlighted the main problem that African countries continue to have in developing vaccine production capabilities: markets for their products.
  • This is a local company that’s developed the capacity to manufacture the vaccine in South Africa through a technology transfer partnership with Pfizer.
  • The tender outcome is truly paradoxical given that South Africa has expressed a strong commitment to local production of medicines.

Market access and local production

    • The tender decision raises important questions about local production and how its inextricably linked to market access.
    • Since 2021, vaccine production initiatives in Africa have mostly focused on financing and partnership building, leaving out the central question of market access for products made in African countries.
    • Market access is crucial for local production of vaccines.
    • If the aim is to enable local vaccine production in Africa, we have to ensure that local producers have access to their national markets.

Procurement


    Procurement policies can potentially promote three broad goals:
    But balancing these three goals is not easy. Focusing just on the lowest prices may in fact, lead to the elimination of local companies, driving them out of business. This is why countries that have succeeded in building local vaccine manufacturing had done so by, among other things:
    • A reliance on preferential procurement by local companies can sometimes have negative consequences.
    • But these can be avoided by designing procurement policies that support local companies more broadly, with a focus on promoting competition.

What Africa needs

    • This basis needs to be preserved and nurtured, to enable the company to expand, and to allow the emergence of a vibrant vaccine production sector in the country that can supply to South Africa and the region.
    • This would help local companies to stabilise themselves in Africa, which are not equipped to absorb the financial risks of losing out on national tenders.
    • Africa has come a long way, in the post-COVID era, in boosting the morale around local production investment among local and foreign companies.
    • Without this commitment from African governments, the Africa vaccine manufacturing “project” is under serious threat.

Aeolian Biotech Corp. Formed to Create an Improved Pneumococcal Vaccine with Experienced Vaccine Development Leadership Team

Retrieved on: 
Monday, January 30, 2023

Aeolian Biotech Corp. today announced the formation and launch of the Company to focus on the development of an improved pneumococcal conjugate vaccine, ‘iPCV22’, to address the threat of circulating and emerging pneumococcal serotypes.

Key Points: 
  • Aeolian Biotech Corp. today announced the formation and launch of the Company to focus on the development of an improved pneumococcal conjugate vaccine, ‘iPCV22’, to address the threat of circulating and emerging pneumococcal serotypes.
  • The management team possesses a diverse set of experiences across vaccine drug development and includes key members of the team that developed the Prevnar family of vaccines.
  • This patent is expected to provide Aeolian with U.S. market exclusivity for its vaccine product until 2036, excluding any possible patent term extensions or patent term adjustments.
  • Mr. O'Neill is an accomplished business development and commercial leader, having held senior roles at Johnson & Johnson and Sanofi-Genzyme, prior to joining Aeolian.

Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

Retrieved on: 
Thursday, January 5, 2023

SAN CARLOS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for VAX-24, the Company’s investigational 24-valent pneumococcal conjugate vaccine (PCV) candidate for the prevention of invasive pneumococcal disease (IPD), in adults. The FDA’s decision was based on positive topline results from the Phase 1/2 proof-of-concept study, which evaluated the safety, tolerability and immunogenicity of VAX-24 in adults 18-64 years of age.

Key Points: 
  • At this dose, VAX-24 met the standard opsonophagocytic activity response non-inferiority criteria for all 20 serotypes common with PCV20, of which 16 achieved higher immune responses.
  • Topline safety, tolerability and immunogenicity data from the pivotal Phase 3 non-inferiority study in adults are expected in 2025.
  • Topline safety, tolerability and immunogenicity data from a Phase 1/2 study in adults 18 years of age and older are expected in 2024.
  • Vaxcyte nominated a final vaccine candidate for VAX-PG, its novel therapeutic vaccine designed to treat periodontal disease, in the fourth quarter of 2022 and continues to progress the program.

$82 Billion Global Vaccines Market 2023 to 2029: Growth Trends, and Market Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023

This is likely to be a continuous booster to the PCV segment in vaccines market.

Key Points: 
  • This is likely to be a continuous booster to the PCV segment in vaccines market.
  • This according to the report will act as a significant driving force for spike in demand for PCV in global vaccines market.
  • These markets are expected to capture around 50% of the overall vaccines market valuation over the next few years.
  • The report marks AMRO as the most prominent vaccines market as the region is characterized by the relatively high value for Influenza (adult), Varicella, meningococcal vaccines, and HPV.

Global Pneumococcal Vaccine Market Report 2022-2027: Rise in Government Focus on Immunization Programs for Pneumonia Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 3, 2023

The Global Pneumococcal Vaccine Market is segmented based on Type, Indication, Product, Distribution, and Geography.

Key Points: 
  • The Global Pneumococcal Vaccine Market is segmented based on Type, Indication, Product, Distribution, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global Pneumococcal Vaccine Market.
  • The analyst analyzes the Global Pneumococcal Vaccine Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Pneumococcal Vaccine Market.

Worldwide Vaccines Industry to 2029 - Combination Vaccines Remain a Significant Growth Contributor to Vaccine Spaces

Retrieved on: 
Friday, January 6, 2023

Escalating investments by vaccine manufacturers, and governments from across the globe is predominantly driving the global vaccines market growth.

Key Points: 
  • Escalating investments by vaccine manufacturers, and governments from across the globe is predominantly driving the global vaccines market growth.
  • While vaccines market (excluding COVID-19 vaccine) is expected to demonstrate nearly 11.2% growth, the market (including COVID-19 vaccine) is likely to experience 3.9% growth through the end of forecast period.
  • Epidemic, and pandemic situations like COVID-19 outbreak act as the key growth influencers for vaccines market, says a newly released market intelligence report of The publisher.
  • On the other hand, demand for seasonal influenza vaccines is projected to remain buoyant and will see the fastest growth through 2029.

Global Human Vaccines Market Report 2022: Growing Prevalence of Emerging and Re-Emerging Infectious Diseases Fuels Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 30, 2022

The Global Human Vaccines Market is segmented based on Technology, Type, Disease Indication, End-Users, and Geography.

Key Points: 
  • The Global Human Vaccines Market is segmented based on Technology, Type, Disease Indication, End-Users, and Geography.
  • By Technology, the market is classified into Conjugate Vaccines, Recombinant Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, and Viral Vector Vaccines.
  • The report presents a detailed Ansoff matrix analysis for the Global Human Vaccines Market.
  • The analyst analyses the Global Human Vaccines Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.